2,718 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,718 shares of the company’s stock, valued at approximately $342,000.

Other large investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its stake in shares of Neurocrine Biosciences by 15.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 447,900 shares of the company’s stock worth $57,331,000 after purchasing an additional 60,094 shares during the period. CWM LLC increased its holdings in Neurocrine Biosciences by 150.3% during the second quarter. CWM LLC now owns 26,289 shares of the company’s stock worth $3,304,000 after buying an additional 15,786 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in Neurocrine Biosciences by 30.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 11,035 shares of the company’s stock worth $1,387,000 after buying an additional 2,577 shares during the last quarter. IFP Advisors Inc raised its position in Neurocrine Biosciences by 4.2% in the second quarter. IFP Advisors Inc now owns 2,172 shares of the company’s stock worth $273,000 after acquiring an additional 88 shares during the period. Finally, Callan Family Office LLC purchased a new position in Neurocrine Biosciences in the second quarter valued at about $285,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $142.65 on Wednesday. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $154.61. The firm has a market cap of $14.15 billion, a PE ratio of 42.20, a PEG ratio of 1.01 and a beta of 0.21. The company has a 50 day simple moving average of $139.27 and a two-hundred day simple moving average of $126.68.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm had revenue of $687.50 million for the quarter, compared to analysts’ expectations of $653.09 million. During the same quarter last year, the company posted $1.63 EPS. The business’s quarterly revenue was up 16.5% on a year-over-year basis. As a group, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on NBIX. Morgan Stanley raised their price target on shares of Neurocrine Biosciences from $163.00 to $168.00 and gave the stock an “overweight” rating in a research note on Monday. Stifel Nicolaus increased their price objective on Neurocrine Biosciences from $166.00 to $174.00 and gave the company a “buy” rating in a report on Thursday, July 31st. UBS Group raised their target price on Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a research note on Thursday, July 10th. They issued a “buy” rating and a $182.00 target price on the stock. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $164.32.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the sale, the director owned 514,596 shares of the company’s stock, valued at $65,050,080.36. The trade was a 17.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.